Overview

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Sanofi
Treatments:
Hydrochlorothiazide
Irbesartan